On September 8, Jim Wilson, director of Penn Medicine’s gene therapy program and director of Penn’s orphan disease center. sat down with health care reporter John George for a wide-ranging discussion to kick off the Philadelphia Business Journal event “From Research to Real Estate: What’s next for cell and gene therapy in Philadelphia.” In the interview, Wilson, who has been involved in the launch of eight gene therapy and gene-editing companies and alliances, explains what attracted him to Penn, current life sciences trends, and the future of gene therapy.
Moving forward, he said, “is going to require that we’re creative and innovative, not only in the technology, but how we build more efficient businesses and develop simpler and better commercial models.”
To read the in-depth interview in the Philadelphia Business Journal, go here.
